You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTerfenadine
Accession NumberDB00342  (APRD00606)
TypeSmall Molecule
GroupsWithdrawn
DescriptionIn the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Structure
Thumb
Synonyms
(RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-ol
Terfenadin
Terfenadina
Terfénadine
Terfenadine
Terfenadinum
External Identifiers
  • RMI 9918
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Allergy ReliefTablet60 mgOralJcp Laboratories Inc.1994-12-311998-08-12Canada
Novo-terfenadine Tab 60mgTablet60 mgOralNovopharm Limited1993-12-311999-11-15Canada
Safeway Once A Day Allergy Caplet 120mgTablet120 mgOralJcp Laboratories Inc.1991-12-311997-01-13Canada
Seldane - Sus 30mg/5mlSuspension30 mgOralHoechst Marion Roussel Canada Inc.1995-12-311998-08-12Canada
Seldane - Tab 60mgTablet60 mgOralHoechst Marion Roussel Canada Inc.1996-10-071998-08-12Canada
Seldane 120mg Once-A-day CapletsTablet120 mgOralHoechst Marion Roussel Canada Inc.1995-12-311998-08-12Canada
Seldane Sus 6mg/mlSuspension6 mgOralMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1985-12-311996-09-09Canada
Seldane Tab 120mgTablet120 mgOralMerrell Dow Pharmaceuticals (Canada) Inc., Division Of Mmdc1988-12-311997-08-05Canada
Seldane Tab 60mgTablet60 mgOralMerrell Pharms Inc., Division Of Merrell Dow (Can)1983-12-311997-08-05Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-terfenadine Tab 120mgTablet120 mgOralApotex Inc1993-12-311999-12-08Canada
Apo-terfenadine Tablets 60mgTablet60 mgOralApotex Inc1993-12-311999-12-08Canada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BronalGalenika
DaylertMicro Labs
SeldaneNot Available
ServininNovartis
TeldaneNot Available
TerfedCipla
Terfenadin ALAliud
Terfenadine FLXAccord Healthcare
TerfinInterbat
TernadinDunar
TrexylRanbaxy
TriludanNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7BA5G9Y06Q
CAS number50679-08-8
WeightAverage: 471.6734
Monoisotopic: 471.313729561
Chemical FormulaC32H41NO2
InChI KeyGUGOEEXESWIERI-UHFFFAOYSA-N
InChI
InChI=1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3
IUPAC Name
1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol
SMILES
CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Pharmacology
IndicationFor the treatment of allergic rhinitis, hay fever, and allergic skin disorders.
Structured Indications Not Available
PharmacodynamicsTerfenadine, an H1-receptor antagonist antihistamine, is similar in structure to astemizole and haloperidol, a butyrophenone antipsychotic. The active metabolite of terfenadine is fexofenadine.
Mechanism of actionTerfenadine competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of terfenadine to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier, CNS depression is minimal.
TargetKindPharmacological actionActionsOrganismUniProt ID
Histamine H1 receptorProteinyes
antagonist
HumanP35367 details
Potassium voltage-gated channel subfamily H member 2Proteinunknown
inhibitor
HumanQ12809 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M1Proteinunknown
binder
HumanP11229 details
Muscarinic acetylcholine receptor M5Proteinunknown
binder
HumanP08912 details
Muscarinic acetylcholine receptor M4Proteinunknown
binder
HumanP08173 details
Muscarinic acetylcholine receptor M2Proteinunknown
binder
HumanP08172 details
Related Articles
AbsorptionOn the basis of a mass balance study using 14C labeled terfenadine the oral absorption of terfenadine was estimated to be at least 70%
Volume of distributionNot Available
Protein binding70%
Metabolism

Hepatic

SubstrateEnzymesProduct
Terfenadine
fexofenadineDetails
Route of eliminationNot Available
Half life3.5 hours
ClearanceNot Available
ToxicityMild (e.g., headache, nausea, confusion), but adverse cardiac events including cardiac arrest, ventricular arrhythmias including torsades de pointes and QT prolongation have been reported. LD50=mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Terfenadine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Terfenadine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Terfenadine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Terfenadine.Experimental, Illicit
AbirateroneThe serum concentration of Terfenadine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Terfenadine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Terfenadine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Terfenadine.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Terfenadine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Terfenadine.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Terfenadine.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Terfenadine.Approved, Investigational
AmiodaroneThe serum concentration of Terfenadine can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Terfenadine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Terfenadine.Approved
AmphetamineAmphetamine may decrease the sedative activities of Terfenadine.Approved, Illicit
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Terfenadine.Approved
AprepitantThe serum concentration of Terfenadine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Terfenadine.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Terfenadine.Approved, Investigational
ArtemetherThe metabolism of Terfenadine can be decreased when combined with Artemether.Approved
AtazanavirThe serum concentration of Terfenadine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Terfenadine.Approved
AtomoxetineThe metabolism of Terfenadine can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Terfenadine.Approved, Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Terfenadine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Terfenadine.Approved, Illicit
Benzylpenicilloyl PolylysineTerfenadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Terfenadine.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Terfenadine.Approved, Vet Approved
BetaxololThe metabolism of Terfenadine can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Terfenadine can be decreased when it is combined with Bexarotene.Approved, Investigational
BicalutamideThe serum concentration of Terfenadine can be increased when it is combined with Bicalutamide.Approved
BoceprevirThe serum concentration of Terfenadine can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Terfenadine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Terfenadine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Terfenadine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Terfenadine.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Terfenadine.Approved, Investigational
BupropionThe metabolism of Terfenadine can be decreased when combined with Bupropion.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Terfenadine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Terfenadine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Terfenadine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Terfenadine.Approved
CapecitabineThe metabolism of Terfenadine can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Terfenadine can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinCarbomycin may increase the QTc-prolonging activities of Terfenadine.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Terfenadine.Approved
CelecoxibThe metabolism of Terfenadine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Terfenadine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Terfenadine.Withdrawn
ChloroquineThe metabolism of Terfenadine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Terfenadine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Terfenadine.Approved, Vet Approved
CholecalciferolThe metabolism of Terfenadine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Terfenadine.Approved
CinacalcetThe metabolism of Terfenadine can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Terfenadine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Terfenadine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Terfenadine.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Terfenadine.Approved
ClemastineThe metabolism of Terfenadine can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Terfenadine.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Terfenadine.Approved, Investigational
ClomipramineThe metabolism of Terfenadine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Terfenadine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Terfenadine.Approved, Nutraceutical
ClotrimazoleThe metabolism of Terfenadine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Terfenadine.Approved
CobicistatThe serum concentration of Terfenadine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Terfenadine.Approved
CocaineThe metabolism of Terfenadine can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Terfenadine.Approved
ConivaptanThe serum concentration of Terfenadine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Terfenadine.Approved
CrizotinibThe metabolism of Terfenadine can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Terfenadine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Terfenadine.Approved
DabrafenibThe serum concentration of Terfenadine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Terfenadine.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Terfenadine.Approved
DarifenacinThe metabolism of Terfenadine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Terfenadine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Terfenadine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Terfenadine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Terfenadine.Approved
DeferasiroxThe serum concentration of Terfenadine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineDelavirdine may increase the arrhythmogenic activities of Terfenadine.Approved
DesipramineThe metabolism of Terfenadine can be decreased when combined with Desipramine.Approved
DexamethasoneThe serum concentration of Terfenadine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Terfenadine.Approved, Illicit
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Terfenadine.Approved, Illicit, Vet Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Terfenadine.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Terfenadine.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Terfenadine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Terfenadine.Approved
DihydroergotamineThe metabolism of Terfenadine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Terfenadine.Illicit
DiltiazemThe metabolism of Terfenadine can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Terfenadine can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Terfenadine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Terfenadine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Terfenadine.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Terfenadine.Approved, Investigational
DoxycyclineThe metabolism of Terfenadine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Terfenadine can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Terfenadine can be decreased when combined with Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Terfenadine.Approved
EfavirenzThe serum concentration of Terfenadine can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Terfenadine.Approved, Investigational
EliglustatThe metabolism of Terfenadine can be decreased when combined with Eliglustat.Approved
EnzalutamideThe serum concentration of Terfenadine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Terfenadine.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Terfenadine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Terfenadine.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Terfenadine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Terfenadine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Terfenadine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Terfenadine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Terfenadine.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Terfenadine.Approved
EtravirineThe serum concentration of Terfenadine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Terfenadine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Terfenadine.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Terfenadine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Terfenadine.Approved
FidaxomicinFidaxomicin may increase the QTc-prolonging activities of Terfenadine.Approved
FloxuridineThe metabolism of Terfenadine can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Terfenadine can be decreased when combined with Fluconazole.Approved
FluorouracilThe metabolism of Terfenadine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Terfenadine can be decreased when combined with Fluoxetine.Approved, Vet Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Terfenadine.Approved
FluvastatinThe metabolism of Terfenadine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Terfenadine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Terfenadine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Terfenadine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Terfenadine can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Terfenadine can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Terfenadine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Terfenadine.Approved
GemfibrozilThe metabolism of Terfenadine can be decreased when combined with Gemfibrozil.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Terfenadine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Terfenadine.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Terfenadine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Terfenadine.Approved, Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Terfenadine.Approved, Vet Approved
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Terfenadine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Terfenadine.Approved
IdelalisibThe serum concentration of Terfenadine can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Terfenadine can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Terfenadine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Terfenadine.Approved
IndinavirThe serum concentration of Terfenadine can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Terfenadine.Approved, Investigational
IrbesartanThe metabolism of Terfenadine can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Terfenadine.Approved, Investigational
IsavuconazoniumThe metabolism of Terfenadine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Terfenadine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Terfenadine can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Terfenadine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Terfenadine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Terfenadine.Approved, Vet Approved
JosamycinJosamycin may increase the QTc-prolonging activities of Terfenadine.Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Terfenadine.Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Terfenadine.Approved, Investigational
KetoconazoleThe serum concentration of Terfenadine can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinKitasamycin may increase the QTc-prolonging activities of Terfenadine.Experimental
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Terfenadine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Terfenadine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Terfenadine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Terfenadine.Approved
LeflunomideThe metabolism of Terfenadine can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Terfenadine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Terfenadine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Terfenadine.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Terfenadine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Terfenadine.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Terfenadine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Terfenadine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Terfenadine.Approved
LopinavirThe serum concentration of Terfenadine can be increased when it is combined with Lopinavir.Approved
LorcaserinThe metabolism of Terfenadine can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Terfenadine.Approved
LovastatinThe metabolism of Terfenadine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Terfenadine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Terfenadine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Terfenadine can be decreased when combined with Lumefantrine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Terfenadine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Terfenadine.Investigational
MephentermineMephentermine may decrease the sedative activities of Terfenadine.Approved
MethadoneThe metabolism of Terfenadine can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may decrease the sedative activities of Terfenadine.Approved, Illicit
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Terfenadine.Approved
MethotrimeprazineThe metabolism of Terfenadine can be decreased when combined with Methotrimeprazine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Terfenadine.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Terfenadine.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Terfenadine.Approved, Illicit
MifepristoneThe serum concentration of Terfenadine can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Terfenadine.Approved
MitotaneThe serum concentration of Terfenadine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Terfenadine.Approved, Investigational
MMDAMMDA may decrease the sedative activities of Terfenadine.Experimental, Illicit
ModafinilThe serum concentration of Terfenadine can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Terfenadine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Terfenadine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Terfenadine.Approved
NafcillinThe serum concentration of Terfenadine can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Terfenadine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Terfenadine.Approved, Vet Approved
NefazodoneThe serum concentration of Terfenadine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Terfenadine can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Terfenadine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Terfenadine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Terfenadine can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Terfenadine.Approved
NilotinibThe metabolism of Terfenadine can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Terfenadine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Terfenadine.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Terfenadine.Approved, Investigational
OlaparibThe metabolism of Terfenadine can be decreased when combined with Olaparib.Approved
OleandomycinOleandomycin may increase the QTc-prolonging activities of Terfenadine.Vet Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Terfenadine.Approved
OmeprazoleThe metabolism of Terfenadine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Terfenadine can be increased when it is combined with Osimertinib.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Terfenadine.Approved, Vet Approved
PalbociclibThe serum concentration of Terfenadine can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Terfenadine can be increased when it is combined with Panobinostat.Approved, Investigational
ParoxetineThe metabolism of Terfenadine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Terfenadine.Approved
Peginterferon alfa-2bThe serum concentration of Terfenadine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Terfenadine can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Terfenadine can be increased when combined with Phenobarbital.Approved
PhenterminePhentermine may decrease the sedative activities of Terfenadine.Approved, Illicit
PhenytoinThe metabolism of Terfenadine can be increased when combined with Phenytoin.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Terfenadine.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Terfenadine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Terfenadine.Approved
PosaconazoleThe serum concentration of Terfenadine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Terfenadine.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Terfenadine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Terfenadine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Terfenadine.Approved, Vet Approved
PrimidoneThe metabolism of Terfenadine can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Terfenadine.Approved, Vet Approved
PromazineThe metabolism of Terfenadine can be decreased when combined with Promazine.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Terfenadine.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Terfenadine.Approved
PseudoephedrinePseudoephedrine may decrease the sedative activities of Terfenadine.Approved
PyrimethamineThe metabolism of Terfenadine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Terfenadine.Approved
QuinidineThe metabolism of Terfenadine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Terfenadine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Terfenadine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Terfenadine.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Terfenadine.Approved
RifabutinThe metabolism of Terfenadine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Terfenadine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Terfenadine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Terfenadine.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Terfenadine.Approved, Investigational
RitobegronRitobegron may decrease the sedative activities of Terfenadine.Investigational
RitonavirThe serum concentration of Terfenadine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Terfenadine.Approved
RolapitantThe metabolism of Terfenadine can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Terfenadine.Approved, Investigational
RopiniroleThe metabolism of Terfenadine can be decreased when combined with Ropinirole.Approved, Investigational
RoxithromycinRoxithromycin may increase the QTc-prolonging activities of Terfenadine.Approved, Withdrawn
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Terfenadine.Approved, Vet Approved
SaquinavirThe serum concentration of Terfenadine can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Terfenadine.Approved
SecobarbitalThe metabolism of Terfenadine can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Terfenadine.Approved
SertralineThe metabolism of Terfenadine can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Terfenadine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Terfenadine.Approved
SiltuximabThe serum concentration of Terfenadine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Terfenadine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Terfenadine.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Terfenadine.Approved
SolithromycinSolithromycin may increase the QTc-prolonging activities of Terfenadine.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Terfenadine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Terfenadine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Terfenadine.Experimental
SpiramycinSpiramycin may increase the QTc-prolonging activities of Terfenadine.Approved
St. John's WortThe serum concentration of Terfenadine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Terfenadine can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Terfenadine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Terfenadine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Terfenadine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Terfenadine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Terfenadine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Terfenadine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Terfenadine.Approved
TelaprevirThe serum concentration of Terfenadine can be increased when it is combined with Telaprevir.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Terfenadine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Terfenadine.Approved
TerbinafineThe metabolism of Terfenadine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Terfenadine.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Terfenadine.Approved
TiclopidineThe metabolism of Terfenadine can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Terfenadine.Approved
TipranavirThe metabolism of Terfenadine can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Terfenadine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Terfenadine can be decreased when combined with Tolbutamide.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Terfenadine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Terfenadine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Terfenadine.Approved, Investigational
TranylcypromineThe metabolism of Terfenadine can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Terfenadine.Approved
TrimethoprimThe metabolism of Terfenadine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TroleandomycinTroleandomycin may increase the QTc-prolonging activities of Terfenadine.Approved
TylosinTylosin may increase the QTc-prolonging activities of Terfenadine.Vet Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Terfenadine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Terfenadine.Approved
Valproic AcidThe metabolism of Terfenadine can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Terfenadine can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Terfenadine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Terfenadine.Approved
VenlafaxineThe metabolism of Terfenadine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Terfenadine can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Terfenadine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Terfenadine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Terfenadine.Approved
VoriconazoleThe serum concentration of Terfenadine can be increased when it is combined with Voriconazole.Approved, Investigational
ZafirlukastThe metabolism of Terfenadine can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Terfenadine.Approved
ZiprasidoneThe metabolism of Terfenadine can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Timothy G. Fawcett, Christian T. Goralski, David W. Ziettlow, “Preparation of polymorphically pure terfenadine.” U.S. Patent US4742175, issued April, 1975.

US4742175
General ReferencesNot Available
External Links
ATC CodesR06AX12
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9535
Blood Brain Barrier+0.5319
Caco-2 permeable+0.6691
P-glycoprotein substrateSubstrate0.8338
P-glycoprotein inhibitor IInhibitor0.7145
P-glycoprotein inhibitor IIInhibitor0.5515
Renal organic cation transporterInhibitor0.5731
CYP450 2C9 substrateNon-substrate0.8286
CYP450 2D6 substrateSubstrate0.7689
CYP450 3A4 substrateSubstrate0.6664
CYP450 1A2 substrateInhibitor0.5553
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.5229
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9627
Ames testNon AMES toxic0.8907
CarcinogenicityNon-carcinogens0.8443
BiodegradationNot ready biodegradable0.9683
Rat acute toxicity2.0063 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5556
hERG inhibition (predictor II)Inhibitor0.8014
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Veratex Corp.
Dosage forms
FormRouteStrength
TabletOral60 mg
TabletOral120 mg
SuspensionOral30 mg
SuspensionOral6 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point147 °CPhysProp
water solubility0.0963 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP7.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000458 mg/mLALOGPS
logP5.89ALOGPS
logP6.48ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)13.2ChemAxon
pKa (Strongest Basic)9.02ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area43.7 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity146.27 m3·mol-1ChemAxon
Polarizability56.45 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-8890000000-2c6ad1195e498f463cbfView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylbutylamine
  • Phenylpropane
  • Aralkylamine
  • Piperidine
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kishimoto W, Hiroi T, Sakai K, Funae Y, Igarashi T: Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92. [PubMed:9485522 ]
  3. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF 3rd, Guinosso PJ Jr, Lynch JJ Jr: Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 1995 Jan;76(1):110-9. [PubMed:8001268 ]
  4. Wood-Baker R, Smith R, Holgate ST: A double-blind, placebo controlled study of the effect of the specific histamine H1-receptor antagonist, terfenadine, in chronic severe asthma. Br J Clin Pharmacol. 1995 Jun;39(6):671-5. [PubMed:7654486 ]
  5. Phillips GD, Polosa R, Holgate ST: The effect of histamine-H1 receptor antagonism with terfenadine on concentration-related AMP-induced bronchoconstriction in asthma. Clin Exp Allergy. 1989 Jul;19(4):405-9. [PubMed:2569356 ]
  6. Rafferty P, Holgate ST: Terfenadine (Seldane) is a potent and selective histamine H1 receptor antagonist in asthmatic airways. Am Rev Respir Dis. 1987 Jan;135(1):181-4. [PubMed:2879489 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Gessner G, Zacharias M, Bechstedt S, Schonherr R, Heinemann SH: Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents. Mol Pharmacol. 2004 May;65(5):1120-9. [PubMed:15102940 ]
  3. Testai L, Cecchetti V, Sabatini S, Martelli A, Breschi MC, Calderone V: Effects of K openers on the QT prolongation induced by HERG-blocking drugs in guinea-pigs. J Pharm Pharmacol. 2010 Jul;62(7):924-30. doi: 10.1211/jpp.62.06.0014. [PubMed:20636881 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY: Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos. 2000 Mar;28(3):360-6. [PubMed:10681383 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Kishimoto W, Hiroi T, Sakai K, Funae Y, Igarashi T: Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92. [PubMed:9485522 ]
  4. Nemeroff CB, DeVane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996 Mar;153(3):311-20. [PubMed:8610817 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Kishimoto W, Hiroi T, Sakai K, Funae Y, Igarashi T: Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92. [PubMed:9485522 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible for the epoxidation of endogenous cardiac arachidonic acid pools.
Gene Name:
CYP2J2
Uniprot ID:
P51589
Molecular Weight:
57610.165 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  2. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  3. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993 Jan 26;45(2):401-6. [PubMed:8094615 ]
  4. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23